论文部分内容阅读
CA-5是1983年Lindholm 等发现的肿瘤标记物,用大肠癌细胞株colo-205作为抗原制成了单克隆抗体。本文作者收集了健康人67例(男35、女32例)和大肠癌术前患者46例(男女各23例,Ⅱ期15例、Ⅱ期11例、Ⅲ期5例、Ⅳ期5例和Ⅴ期10例)的血清,应用固相酶免疫分析法,研究了大肠癌患者CA-50的临床意义,同时对CA-50、CA19-9和CEA 进行了比较。结果:健康人CA-50平均值为10.6±6.1u/ml其中男性为8.6±5.3u/ml(0.8～21.0),女性为12.9±6.2μ/ml(2.0～27.0)。大肠癌患者平均值为31.7±55.2u/ml,其中男性为26.9±63.7μ/ml
CA-5 is a tumor marker discovered by Lindholm et al. in 1983. A monoclonal antibody was produced using the colorectal cancer cell line colo-205 as an antigen. The authors collected 67 healthy persons (35 males and 32 females) and 46 preoperative patients with colorectal cancer (23 males and 23 females, 15 in the secondary phase, 11 in the secondary phase, 5 in the tertiary phase, 5 in the IV phase, and 5 in the IV phase). In serum of 10 patients with V phase, using solid-phase enzyme immunoassay, the clinical significance of CA-50 in patients with colorectal cancer was studied. CA-50, CA19-9 and CEA were also compared. Results: The average CA-50 of healthy people was 10.6±6.1u/ml, of which males were 8.6±5.3u/ml (0.8～21.0) and females were 12.9±6.2μ/ml (2.0～27.0). The average colorectal cancer patients were 31.7±55.2u/ml, including 26.9±63.7μ/ml for men.